HeartBeat.bio AG

HeartBeat.bio AG is at the forefront of biotechnology research, dedicated to transforming cardiac drug discovery. With a focus on developing breakthrough medicines for heart failure patients, HeartBeat.bio AG addresses a critical global health challenge. The company’s proprietary Cardioid Drug Discovery Platform integrates iPSC-derived cardiac organoids with AI-driven analytics and advanced automation, offering a human-centric approach to drug development. Located at Dr. Bohr-Gasse 7, Vienna Biocenter 6, Vienna, 1030, AT, HeartBeat.bio AG is committed to accelerating drug discovery, reducing failure rates, and bringing novel therapies to patients faster through innovative research and strategic partnerships. HeartBeat.bio AG is advancing its own pipeline and collaborating with pharmaceutical and biotech companies to co-develop transformative heart failure treatments.

HeartBeat.bio AG’s approach enables more predictive, efficient, and cost-effective drug development compared to traditional methods. By focusing on areas such as cardiomyopathies, myocardial fibrosis, and cardiac remodeling, HeartBeat.bio AG addresses high-impact indications with significant unmet needs. HeartBeat.bio AG leverages cutting-edge technology and physiologically relevant human models to drive innovation in the treatment of heart failure, a rapidly growing global health crisis. The company closed a longer-term partnership deal with a leading player in cardiovascular disease.

HeartBeat.bio AG’s commitment to excellence and innovation positions it as a leader in the biotechnology sector. The company's focus on heart regeneration, cardiotoxicity, and myocardial infarction underscores its dedication to improving patient outcomes and advancing medical science. HeartBeat.bio AG is dedicated to making a significant impact on global healthcare. We invite the management of HeartBeat.bio AG to create a customized and exclusive company showcase and product listing on our platform.